We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies
Read MoreHide Full Article
Eli Lilly & Company’s (LLY - Free Report) subsidiary, Loxo Oncology announced a deal with Netherlands’ Merus N.V. (MRUS - Free Report) to discover up to three novel T-cell re-directing bispecific antibodies for cancer. The potential medicines will be developed by leveraging Merus’ proprietary CD3 T-cell engager Biclonics platform.
Lilly will make an upfront payment of $40 million to Merus while also investing in the latter’s stock worth $20 million. In addition, Merus will also be eligible to receive up to $540 million in potential milestone payments for one product, which will add up to approximately $1.6 billion for three products. Merus will also be entitled to royalties on sales of any product, if successfully developed under the deal.
While Merus will lead discovery and early-stage development, Loxo Oncology will take care of further development and commercialization activities. Merus’ shares were up 6% on the announcement of the deal.
In the past year, Lilly’s shares have risen 40.9% compared with the industry’s increase of 4.6%.
Lilly regularly adds promising new pipeline assets through M&A deals. Among the recent deals, in December, Lilly announced a definitive agreement to acquire Prevail Therapeutics for $22.50 per share in cash or an aggregate value of $880 million. The acquisition will add Prevail’s promising gene-therapy candidates, targeting neurodegenerative diseases, to Lilly’s portfolio. In November, Lilly entered into a research collaboration and an exclusive license agreement with North Carolina-based biotech Precision BioSciences (DTIL - Free Report) for using the latter’s proprietary genome editing platform to develop potential in vivo therapies for treating genetic disorders, especially Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Shutterstock
Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies
Eli Lilly & Company’s (LLY - Free Report) subsidiary, Loxo Oncology announced a deal with Netherlands’ Merus N.V. (MRUS - Free Report) to discover up to three novel T-cell re-directing bispecific antibodies for cancer. The potential medicines will be developed by leveraging Merus’ proprietary CD3 T-cell engager Biclonics platform.
Lilly will make an upfront payment of $40 million to Merus while also investing in the latter’s stock worth $20 million. In addition, Merus will also be eligible to receive up to $540 million in potential milestone payments for one product, which will add up to approximately $1.6 billion for three products. Merus will also be entitled to royalties on sales of any product, if successfully developed under the deal.
While Merus will lead discovery and early-stage development, Loxo Oncology will take care of further development and commercialization activities. Merus’ shares were up 6% on the announcement of the deal.
In the past year, Lilly’s shares have risen 40.9% compared with the industry’s increase of 4.6%.
Lilly regularly adds promising new pipeline assets through M&A deals. Among the recent deals, in December, Lilly announced a definitive agreement to acquire Prevail Therapeutics for $22.50 per share in cash or an aggregate value of $880 million. The acquisition will add Prevail’s promising gene-therapy candidates, targeting neurodegenerative diseases, to Lilly’s portfolio. In November, Lilly entered into a research collaboration and an exclusive license agreement with North Carolina-based biotech Precision BioSciences (DTIL - Free Report) for using the latter’s proprietary genome editing platform to develop potential in vivo therapies for treating genetic disorders, especially Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.
Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>